Asahi Kasei will acquire Calliditas Therapeutics and with it Tarpeyo, a treatment for primary immunoglobulin A nephropathy.
Asahi Kasei Corp. announces that Asahi Kasei will offer the shareholders of Calliditas Therapeutics to acquire the shares of the pharmaceutical company Calliditas for the purpose of making Calliditas a whollyowned subsidiary of Asahi Kasei through a voluntary tender offer for Calliditas.
The Tender Offer will also include a concurrent offer by Asahi Kasei to acquire all American Depositary Shares each representing two shares in Calliditas, which will be conducted pursuant to the securities rules of the United State. Calliditas is a differentiated specialty pharmaceutical company focused on treating unmet medical needs, with a strong track record of drug development and commercialization led by a highly regarded management organization. Calliditas’ product, Tarpeyo, is highly complementary to Asahi Kasei’s existing geographic and therapeutic areas and treats a rare disease called IgA nephropathy, currently the only fully approved product shown to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy who are at risk for disease progression.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins